文献速递哮喘

Fevipiprant减少重症哮喘急性发作的疗效:LUSTER-1和LUSTER-2两项3期随机对照试验

Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.
PubMed 文献 · Lancet Respir Med · 2020-09-24

LUSTER-1和LUSTER-2两项3期随机双盲安慰剂对照52周研究评估口服前列腺素D2受体2拮抗剂fevipiprant对重症哮喘急性发作的影响。结果显示,在校正多重检验后,两项试验均未显示哮喘急性发作的统计学显著减少,但450 mg剂量在两项研究中均观察到一致且适度的急性发作率降低。

要点

  • 总体人群中,两项试验各剂量组与安慰剂比较的急性发作率比均无统计学显著性。
  • 450 mg剂量在两项研究中均显示一致且适度的急性发作率降低,但未达统计学显著。

核心结论

  • 尽管两项试验在校正多重检验后均未显示哮喘急性发作的统计学显著减少,但450 mg fevipiprant在两项研究中均观察到一致且适度的急性发作率降低。

研究设计与样本

  • LUSTER-1和LUSTER-2为两项3期随机、双盲、安慰剂对照、平行组、重复52周研究。
  • LUSTER-1在25个国家174个中心开展,LUSTER-2在19个国家169个中心开展。
  • 纳入≥12岁、接受GINA第4或5级治疗仍控制不佳的重症哮喘患者,随机接受每日一次fevipiprant 150 mg、450 mg或安慰剂(1:1:1)。
  • LUSTER-1随机894例(150 mg n=301,450 mg n=295,安慰剂 n=298);LUSTER-2随机877例(150 mg n=296,450 mg n=294,安慰剂 n=287)。
  • 主要疗效终点为52周内中重度哮喘急性发作的年化率,在高血嗜酸性粒细胞(≥250/μL)人群和总体人群中比较fevipiprant与安慰剂。

主要发现

  • 两项研究合并总体人群中,严重不良事件发生率:fevipiprant 150 mg组53例(9%),450 mg组50例(9%),安慰剂组50例(9%)。
  • 导致死亡的不良事件:fevipiprant 450 mg组2例(<1%),安慰剂组3例(<1%)。

临床怎么用

  • 对于接受GINA第4或5级治疗的重症哮喘患者,fevipiprant 450 mg每日一次可能适度降低急性发作率,但证据未达统计学显著性,需结合个体情况谨慎评估。

局限性

  • 两项试验的主要终点在校正多重检验后均未达到统计学显著性。
  • 高嗜酸性粒细胞人群中仅LUSTER-2的150 mg组显示统计学显著减少,结果不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fevipiprant, an oral antagonist of the prostaglandin D2 receptor 2, reduced sputum eosinophils and improved lung function in phase 2 trials of patients with asthma. We aimed to investigate whether fevipiprant reduces asthma exacerbations in patients with severe asthma. METHODS: LUSTER-1 and LUSTER-2 were two phase 3 randomised, double-blind, placebo-controlled, parallel-group, replicate 52-week studies; LUSTER-1 took place at 174 clinical sites in 25 countries and LUSTER 2 took place at 169 clinical sites in 19 countries. Fevipiprant or placebo was added to Global Initiative for Asthma Steps 4 and 5 therapy in adolescents and adults with severe asthma. Patients aged 12 years or older with uncontrolled asthma on dual or triple asthma therapy were randomly assigned by use of interactive response technology to one of three treatment groups (once-daily fevipiprant 150 mg, fevipiprant 450 mg, or placebo) in a 1:1:1 ratio within each of the randomisation strata: peripheral blood eosinophil counts (<250 cells per μL or ≥250 cells per μL), patient age (<18 years or ≥18 years), and use or non-use of oral corticosteroids as part of their standard of care asthma therapy. The primary efficacy endpoint was the annualised rate of moderate to severe asthma exacerbations with 150 mg or 450 mg doses of fevipiprant once daily compared with placebo over 52 weeks, in patients with high blood eosinophil counts (≥250 cells per μL) and in the overall study population. All patients who underwent randomisation and received at least one dose of study medication were included in efficacy and safety analyses. These trials are registered with ClinicalTrials.gov, NCT02555683 (LUSTER-1) and NCT02563067 (LUSTER-2), and are complete and no longer recruiting. FINDINGS: Between Dec 11, 2015, and Oct 25, 2018, 894 patients were randomly assigned to fevipiprant 150 mg (n=301), fevipiprant 450 mg (n=295), or placebo (n=298) in LUSTER-1. Between Dec 3, 2015, and July 10, 2018, 877 patients were randomly assigned to fevipiprant 150 mg (n=296), fevipiprant 450 mg (n=294), or placebo (n=287) in LUSTER-2. In the high eosinophil population, in LUSTER-1 the annualised rate ratio of moderate to severe exacerbations compared with placebo was 1·04 (95% CI 0·77-1·41) for fevipiprant 150 mg and 0·83 (0·61-1·14) for fevipiprant 450 mg, and in LUSTER-2 it was 0·69 (0·50-0·96) for fevipiprant 150 mg and 0·72 (0·52-1·01) for fevipiprant 450 mg. In the overall population, in LUSTER-1 the annualised rate ratio of moderate to severe exacerbations compared with placebo was 0·96 (95% CI 0·75-1·22) for fevipiprant 150 mg and 0·78 (0·61-1·01) for fevipiprant 450 mg and in LUSTER-2 it was 0·82 (0·62-1·07) for fevipiprant 150 mg and 0·76 (0·58-1·00) for fevipiprant 450 mg. In the overall pooled population of both studies, serious adverse events occurred in 53 (9%) patients in the fevipiprant 150 mg group, 50 (9%) in the fevipiprant 450 mg group, and 50 (9%) in the placebo group. Adverse events leading to death occurred in two (<1%) patients in the fevipiprant 450 mg group and three (<1%) in the placebo group. INTERPRETATION: Although neither trial showed a statistically significant reduction in asthma exacerbations after adjusting for multiple testing, consistent and modest reductions in exacerbations rates were observed in both studies with the 450 mg dose of fevipiprant. FUNDING: Novartis.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2020. PMID: 32979986. doi:10.1016/S2213-2600(20)30412-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。